跳至主要内容
临床试验/NCT00569764
NCT00569764Unknown不适用

The Effects of Metabolic Parameters of Aripiprazole in Patients With Schizophrenia

Seoul National Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2007年12月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
100
试验地点
1
主要终点
weight lipid profile : HDL, LDL, total-cholesterol, triglyceride fasting blood glucose

研究概览

简要总结

To measure the long-term changes in weight and plasma lipids after switching antipsychotic treatment to aripiprazole

详细描述

To measure the long-term changes in weight, plasma lipids and fasting blood glucose after switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and in-patients with schizophrenia.

The measurement of weight and lipid profile and fasting blood glucose will be measured at baseline and every 3 months for 1 year.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • DSM-IV diagnosis with schizophrenia
  • who signed an informed consent

排除标准

  • comorbid with substance abuse or substance dependence
  • pregnancy or lactation

结局指标

主要结局

weight lipid profile : HDL, LDL, total-cholesterol, triglyceride fasting blood glucose

时间窗: 1 year

次要结局

  • prolactin ECG(1 year)

研究者

发起方
Seoul National Hospital
申办方类型
Other Gov

研究点 (1)

Loading locations...

相似试验

Effect on Metabolic Parameters of Abilify in SPR | 临床试验